Written by: the Medetone Medical Team
Medically reviewed by: Dr Abdullah
Reading time: 7 minutes · Guidance verified: September 2026
Most explanations of how Mounjaro works stop at "it reduces appetite." That is true, but it misses what actually makes this molecule different from everything that came before it. Mounjaro acts on two receptor systems at once, it was engineered from an unexpected starting point, and one of its best-known effects deliberately fades over time. This guide goes into the pharmacology properly: what the molecule does, where it acts, why a single weekly injection is enough, and how the body clears it. It is written for people who want the real mechanism rather than a summary. Mounjaro is a prescription-only medicine and this article is informational.
The dual-receptor difference
The central fact about how Mounjaro works is that tirzepatide is a single molecule that activates two receptors: the GIP receptor (glucose-dependent insulinotropic polypeptide) and the GLP-1 receptor (glucagon-like peptide-1).
Both GIP and GLP-1 are incretin hormones, released by your gut after eating. Both bind to receptors on the beta cells of the pancreas to enhance insulin release. Earlier medicines in this class act on the GLP-1 receptor alone. Tirzepatide is the first to engage both pathways with one molecule, which is why it is described as a dual agonist.
This matters because GIP and GLP-1 are not redundant. They contribute through partly different routes, so activating both produces effects that single-receptor activation does not fully replicate.
Built from GIP, not from GLP-1
Here is the detail almost every explanation leaves out, and it reframes how Mounjaro works entirely.
Tirzepatide was designed from the structure of native GIP, then modified so that it also binds the GLP-1 receptor. It is a GIP peptide taught to do a second job, not a GLP-1 medicine with an extra feature bolted on.
That origin shows up in the pharmacology. The molecule's activity at the GIP receptor is similar to that of the native GIP hormone, while its activity at the GLP-1 receptor is lower than that of native GLP-1. So the two arms are deliberately unbalanced, not a simple doubling of effect. When people assume a dual agonist is just "twice the GLP-1," this is the detail that corrects them.
What happens in the pancreas
Once bound, the molecule improves glucose control through several mechanisms working together:
- Insulin secretion is stimulated directly, by activating GIP and GLP-1 receptors in the pancreas.
- Insulin sensitivity improves, so the insulin present works more effectively.
- Glucagon concentrations fall. Glucagon is the hormone that signals the liver to release stored sugar, so lowering it reduces glucose entering the bloodstream.
The combined result is lower blood glucose in both the fasting and post-meal states, rather than only after eating.
What happens to appetite
Alongside the pancreatic effects, the molecule decreases food intake. This is the part patients notice first, usually within the first week or two, and it is what makes a reduced-calorie diet sustainable rather than a daily battle against hunger.
The practical experience is feeling satisfied with less food and thinking about food less often, the quieting of what many people call food noise. That is not willpower arriving from nowhere. It is appetite signalling being altered at the receptor level.
Importantly, this effect works alongside diet and physical activity, not instead of them. Every clinical trial that produced the well-known results combined the medicine with both.
Gastric emptying: the effect that fades
Tirzepatide also slows gastric emptying, delaying how quickly food leaves the stomach and slowing post-meal glucose absorption.
The nuance that matters, and that very few explanations mention: this effect is largest after the first dose and diminishes over time. Understanding that single fact explains a great deal of the patient experience. It is why nausea and fullness tend to be most pronounced when you start or step up a dose, and why those symptoms usually settle as treatment continues. It is also why the titration schedule exists in the form it does. Our Mounjaro dosage guide covers the schedule in detail.
Because gastric emptying is slowed, the absorption of other oral medicines taken at the same time can be affected, which is worth raising with your prescriber.
Why once weekly is enough
Understanding how Mounjaro works over a full week comes down to a piece of molecular engineering.
Native incretin hormones are cleared from the body within minutes. Tirzepatide is given as a subcutaneous injection and typically reaches maximum plasma concentration within 8 to 72 hours. It was specifically engineered with a C20 fatty diacid portion that allows it to bind to serum albumin, the most abundant protein in blood. Bound to albumin, the molecule is shielded from rapid clearance, which extends its elimination half-life to roughly 5 days.
That extended half-life is the entire reason a once-weekly injection works. Without the fatty diacid modification, this molecule would need dosing many times a day.
Steady state and dose increases
After starting the 2.5 mg dose, plasma concentration rises and then reaches a steady state, a stable level maintained between weekly injections. The same pattern repeats at each step up: concentration rises to a new steady state, then holds.
This is the pharmacological reason dose increases are spaced at least four weeks apart. The schedule is not arbitrary caution. It allows the drug to reach equilibrium at each level before the next increase, which is also why tolerability improves once you settle at a dose.
How the body clears it
Tirzepatide is broken down by proteolytic cleavage of the peptide backbone, beta oxidation of the C20 fatty diacid, and amide hydrolysis. In plain terms, the body dismantles it the way it handles other peptides and fatty acids, rather than processing it through the liver enzyme systems that many drugs rely on.
Two consequences follow, and both are clinically useful:
- It has a low potential to inhibit or induce CYP enzymes, the liver enzymes responsible for a great many drug interactions.
- Neither renal nor hepatic impairment affects its overall pharmacokinetics, so no dose adjustment is recommended for people with kidney or liver impairment.
That is an unusual and favourable profile, and it is a meaningful part of the answer to how Mounjaro works safely alongside other treatment.
What this means in practice
Putting the mechanism together explains the pattern most patients experience. Appetite changes arrive early because the food-intake effect is immediate. Nausea peaks after starting or increasing a dose, then eases, because the gastric emptying effect is strongest at first. Results accumulate over months because weight change follows sustained reduced intake, not a single pharmacological event. And the weekly rhythm exists because of albumin binding, not convenience.
Access is always through a clinical assessment. Patients in the UK can explore treatment through our partner service Rightangled or at Medetone UK, and in the United States at Medetone US. Elsewhere, you can start an assessment with a licensed clinician.
Frequently asked questions
What makes Mounjaro different from single-agonist medicines?
It activates both the GIP and GLP-1 receptors with one molecule, rather than the GLP-1 receptor alone.
Does it act equally on both receptors?
No. Activity at the GIP receptor is similar to the native hormone, while activity at the GLP-1 receptor is lower than native GLP-1.
Why does the nausea usually improve?
Because the delayed gastric emptying effect is largest after the first dose and diminishes over time, so symptoms tied to it typically ease as treatment continues.
Why only one injection a week?
A C20 fatty diacid binds the molecule to serum albumin, extending the half-life to about 5 days.
Is a dose change needed with kidney or liver problems?
No dose adjustment is recommended, as neither renal nor hepatic impairment affects its overall pharmacokinetics. Your prescriber still reviews your full history.
In summary
How Mounjaro works comes down to a single engineered molecule doing several things at once: activating two incretin receptors with deliberately unequal strength, stimulating insulin while lowering glucagon, improving insulin sensitivity, reducing food intake, and slowing gastric emptying in an effect that fades with time. An albumin-binding fatty diacid stretches its half-life to around five days, making weekly dosing possible. Understanding the mechanism makes the treatment experience, from early appetite changes to easing nausea, considerably less mysterious.
Medical information: this article is for information only and does not replace diagnosis, prescription or medical advice. Mounjaro is a prescription-only medicine. Always follow the instructions given by your prescriber.
References:
ANSM, Agence nationale de sécurité du médicament (France): https://ansm.sante.fr
AEMPS, Agencia Española de Medicamentos y Productos Sanitarios (Spain): https://www.aemps.gob.es
AIFA, Agenzia Italiana del Farmaco (Italy): https://www.aifa.gov.it
CBG-MEB, College ter Beoordeling van Geneesmiddelen (Netherlands): https://www.cbg-meb.nl
BfArM, Bundesinstitut für Arzneimittel und Medizinprodukte (Germany): https://www.bfarm.de
European Medicines Agency, Mounjaro EPAR: https://www.ema.europa.eu/en/medicines/human/EPAR/mounjaro
